Screening Patients With Central Nervous System Tumors for Participation in National Cancer Institute Clinical Trials - Full Text View

Screening Patients With Central Nervous System Tumors for Participation in National Cancer Institute Clinical Trials

This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), April 2008

Sponsors and Collaborators:	NCI - Center for Cancer Research-Medical Oncology National Cancer Institute (NCI)
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00040924

Purpose

RATIONALE: Screening tests may help doctors determine which patients are eligible for treatment on clinical trials.

PURPOSE: This clinical trial is screening patients with central nervous system tumors for participation in National Cancer Institute (NCI) clinical trials.

Condition	Intervention
Brain and Central Nervous System Tumors Lymphoma	Procedure: cytology specimen collection procedure Procedure: physiologic testing

MedlinePlus related topics:

Cancer Lymphoma

Drug Information available for:

Somatotropin Somatropin Prolactin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Screening

Official Title:	Eligibility Screening Of Patients With Central Nervous System Tumors For The National Cancer Institute's (NCI) Clinical Research Protocols

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

Entry onto investigational study [ Designated as safety issue: No ]

Estimated Enrollment:	500
Study Start Date:	April 2002
Estimated Primary Completion Date:	December 2010 (Final data collection date for primary outcome measure)

Detailed Description:

OBJECTIVES:

Evaluate patients with central nervous system tumors for eligibility in NCI primary clinical research protocols.

OUTLINE: Patients undergo various diagnostic procedures and clinical testing to determine eligibility for participation in NCI CNS tumor primary clinical research protocols. Patients undergo imaging scans; laboratory testing of blood, cerebrospinal fluid, bone marrow, urine, and other specimens as needed to determine protocol eligibility; and other specific organ function tests.

PROJECTED ACCRUAL: A maximum of 500 patients will be accrued for this study within 5 years.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Diagnosis of CNS tumor or a history of a CNS tumor
Being evaluated for primary clinical research protocols within NCI

PATIENT CHARACTERISTICS:

Age:

Any age

Performance status:

Not specified

Life expectancy:

Not specified

Hematopoietic:

Not specified

Hepatic:

Not specified

Renal:

Not specified

Other:

No other concurrent serious medical condition that would preclude screening procedures

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

Not specified

Endocrine therapy:

Not specified

Radiotherapy:

Not specified

Surgery:

Not specified

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00040924

Locations


United States, Maryland
	Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office	Recruiting
	Bethesda, Maryland, United States, 20892-1182
	Contact: Clinical Trials Office - Warren Grant Magnusen Clinical Center 888-NCI-1937

Sponsors and Collaborators

NCI - Center for Cancer Research-Medical Oncology

National Cancer Institute (NCI)

Investigators


Principal Investigator:	Howard A. Fine, MD	NCI - Neuro-Oncology Branch

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Study ID Numbers:	CDR0000069420, NCI-02-C-0186
First Received:	July 8, 2002
Last Updated:	November 20, 2008
ClinicalTrials.gov Identifier:	NCT00040924
Health Authority:	Unspecified

Keywords provided by National Cancer Institute (NCI):

childhood infratentorial ependymoma

childhood low-grade cerebral astrocytoma

childhood supratentorial ependymoma

childhood craniopharyngioma

childhood central nervous system germ cell tumor

recurrent adult brain tumor

ACTH-producing pituitary tumor

prolactin-producing pituitary tumor

growth hormone-producing pituitary tumor

recurrent pituitary tumor

TSH producing pituitary tumor

nonfunctioning pituitary tumor

adult brain stem glioma

adult craniopharyngioma

adult medulloblastoma

adult meningioma

adult glioblastoma

pituitary basophilic adenoma

prolactin secreting adenoma

pituitary eosinophilic adenoma

TSH secreting adenoma

pituitary chromophobe adenoma

childhood high-grade cerebral astrocytoma

childhood oligodendroglioma

adult anaplastic astrocytoma

childhood choroid plexus tumor

childhood grade I meningioma

childhood grade II meningioma

childhood grade III meningioma

adult oligodendroglioma

Study placed in the following topic categories:

Glioblastoma

Choroid Plexus Neoplasms

Rhabdoid Tumor

Neuroectodermal Tumors, Primitive

Central Nervous System Neoplasms

Pituitary Neoplasms

Ependymoma

Central nervous system lymphoma, primary

Craniopharyngioma

Neuroepithelioma

Meningioma

Glioma

Choroid Plexus neoplasms

Lymphoma

Nervous System Neoplasms

Immunoproliferative Disorders

Spinal cord neoplasm

Astrocytoma

Prolactinoma

Hemangiopericytoma

Recurrence

Rhabdoid tumor

Lymphatic Diseases

Neuroectodermal Tumors

Brain Neoplasms

Medulloblastoma

Spinal Cord Neoplasms

Oligodendroglioma

Gliosarcoma

Lymphoproliferative Disorders

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Site

Neoplasms by Histologic Type

Immune System Diseases

Nervous System Diseases

ClinicalTrials.gov processed this record on November 20, 2008